CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

GVHD,Acute Clinical Trial

Official title:

CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05718791
• Other study ID #: hhf
• Status: Recruiting
• Start date: May 10, 2023
• Est. completion date: March 30, 2026

Study information

• Verified date: April 2024
• Source: Henry Ford Health System
• Contact: shatha farhan, MD
• Phone: 3137133910
• Email: sfarhan1[@]hfhs.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 30, 2026
• Est. primary completion date: March 30, 2026
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients >18 year old admitted for allo SCT PB for malignant disease.

Related Conditions & MeSH terms

• Graft vs Host Disease
• GVHD,Acute

Intervention

Diagnostic Test:
• blood sample
blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Locations

Country	Name	City	State
United States	Henry Ford Health System	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	predictors of acute GVHD	CXCL9 combined with EASIX can be used as predictors of acute GVHD	CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.